JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.
<h4>Purpose</h4>The influence of JAK2 V617F mutation on blast transformation (BT) and overall survival (OS) in primary myelofibrosis (PMF) is controversial. In a large cohort of patients we applied competing risks analysis for studying the influence of JAK2V617F mutation on BT in PMF.<...
Guardado en:
Autores principales: | Giovanni Barosi, Valentina Poletto, Margherita Massa, Rita Campanelli, Laura Villani, Elisa Bonetti, Gianluca Viarengo, Paolo Catarsi, Catherine Klersy, Vittorio Rosti |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/62b9e45bc5d548c6a06efc5fec3c0200 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
por: Giovanni Barosi, et al.
Publicado: (2012) -
New Markers of Disease Progression in Myelofibrosis
por: Rita Campanelli, et al.
Publicado: (2021) -
VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis
por: Laura Villani, et al.
Publicado: (2021) -
Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane C, et al.
Publicado: (2013) -
Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
por: Keohane C, et al.
Publicado: (2013)